This risk is dramatically higher with high-potency, non-FDA-approved products
10.1016/j.jclinane.2024.111668 [DOI] [PubMed] [Google Scholar] 24.Kobori T, Onishi Y, Yoshida Y, Tahara T, Kikuchi T, Kubota T et al (2023) Association of glucagon-like peptide-1 receptor agonist treatment with gastric residue in an esophagogastroduodenoscopy
Homan J, Betzel B, Aarts EO, van Laarhoven KJ, Janssen IM, Berends FJ
With awareness of the health risks especially associated with obesity, there's a growing demand for effective weight management solutions
PMID 12539938
If youre considering weight loss treatment, speak with a healthcare provider about evidence-based options appropriate for your individual circumstances